PMID- 37939825
OWN - NLM
STAT- MEDLINE
DCOM- 20231120
LR  - 20240115
IS  - 1532-2092 (Electronic)
IS  - 1099-5129 (Print)
IS  - 1099-5129 (Linking)
VI  - 25
IP  - 11
DP  - 2023 Nov 2
TI  - Rationale and design of a randomized trial of the dapagliflozin evaluation on 
      atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study.
LID - 10.1093/europace/euad333 [doi]
LID - euad333
AB  - AIMS: Dapagliflozin has been widely used for the treatment of type 2 diabetes 
      mellitus (T2DM) and heart failure (HF). However, data concerning the association 
      between dapagliflozin and the recurrence of atrial fibrillation (AF), especially 
      in patients following Cox-Maze IV (CMIV), are rare. We aim to explore the effect 
      of dapagliflozin on the recurrence of AF after CMIV with and without T2DM or HF. 
      METHODS AND RESULTS: The study of dapagliflozin evaluation in AF patients 
      followed by CMIV (DETAIL-CMIV) is a prospective, double-blind, randomized, 
      placebo-controlled trial. A total of 240 AF patients who have received the CMIV 
      procedure will be randomized into the dapagliflozin group (10 mg/day, n = 120) 
      and the placebo group (10 mg/day, n = 120) and treated for 3 months. The primary 
      endpoint is any documented atrial tachyarrhythmia (AF, atrial flutter or atrial 
      tachycardia) lasting 30 s following a blanking period of 3 months after CMIV. 
      CONCLUSION: DETAIL-CMIV will determine whether the sodium-glucose cotransporter-2 
      inhibitor dapagliflozin, added to guideline-recommended post-operative AF 
      therapies, safely reduces the recurrence rate of AF in patients with and without 
      T2DM or HF.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the 
      European Society of Cardiology.
FAU - Peng, Zhan
AU  - Peng Z
AUID- ORCID: 0000-0002-4621-1968
AD  - Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing Institute of Heart, Lung and Vessel Disease, 2# Anzhen Road, 
      Cao Yang District, Beijing 100029, China.
FAU - Osmanaj, Florian
AU  - Osmanaj F
AD  - Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing Institute of Heart, Lung and Vessel Disease, 2# Anzhen Road, 
      Cao Yang District, Beijing 100029, China.
FAU - Yang, Yunxiao
AU  - Yang Y
AUID- ORCID: 0000-0001-7921-2484
AD  - Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing Institute of Heart, Lung and Vessel Disease, 2# Anzhen Road, 
      Cao Yang District, Beijing 100029, China.
FAU - Hua, Kun
AU  - Hua K
AUID- ORCID: 0000-0002-2189-3632
AD  - Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing Institute of Heart, Lung and Vessel Disease, 2# Anzhen Road, 
      Cao Yang District, Beijing 100029, China.
FAU - Yang, Xiubin
AU  - Yang X
AUID- ORCID: 0009-0008-2318-5227
AD  - Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing Institute of Heart, Lung and Vessel Disease, 2# Anzhen Road, 
      Cao Yang District, Beijing 100029, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Europace
JT  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal 
      of the working groups on cardiac pacing, arrhythmias, and cardiac cellular 
      electrophysiology of the European Society of Cardiology
JID - 100883649
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Humans
MH  - *Atrial Fibrillation/diagnosis/drug therapy/surgery
MH  - Prospective Studies
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - *Catheter Ablation/methods
MH  - *Heart Failure/surgery
MH  - Treatment Outcome
PMC - PMC10655060
OTO - NOTNLM
OT  - Atrial fibrillation
OT  - Cox-Maze IV
OT  - Dapagliflozin
OT  - Recurrence
COIS- Conflict of interest: None declared
EDAT- 2023/11/09 00:42
MHDA- 2023/11/20 06:55
PMCR- 2023/11/06
CRDT- 2023/11/08 19:14
PHST- 2023/07/18 00:00 [received]
PHST- 2023/11/02 00:00 [accepted]
PHST- 2023/11/20 06:55 [medline]
PHST- 2023/11/09 00:42 [pubmed]
PHST- 2023/11/08 19:14 [entrez]
PHST- 2023/11/06 00:00 [pmc-release]
AID - 7367867 [pii]
AID - euad333 [pii]
AID - 10.1093/europace/euad333 [doi]
PST - ppublish
SO  - Europace. 2023 Nov 2;25(11):euad333. doi: 10.1093/europace/euad333.